HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Kura Oncology (NASDAQ:KURA) and maintained a $32 price target.
March 06, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Kura Oncology with a $32 price target, indicating a positive outlook on the stock.
The reiteration of a Buy rating and maintenance of a $32 price target by a reputable analyst firm like HC Wainwright & Co. suggests a strong belief in Kura Oncology's future performance. This endorsement is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100